Effect of type 2 diabetes on recurrent major cardiovascular events for patients with symptomatic vascular disease at different locations

Diabetes Care

Volumn 38, Issue 8, 2015, Pages 1528-1535

  Stam Slob, Manon C ^a   Van Der Graaf, Yolanda ^a   De Borst, Gert Jan ^a   Cramer, Maarten J ^a   Kappelle, L J ^a   Westerink, Jan ^a   Visseren, Frank L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYVASCULAR DISEASE; PREVALENCE; PROSPECTIVE STUDY; RECURRENT DISEASE; VASCULAR DISEASE; AGED; AORTIC ANEURYSM, ABDOMINAL; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; MIDDLE AGED; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE;

AGED; AORTIC ANEURYSM, ABDOMINAL; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE; RECURRENCE;

EID: 84962345974     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2900     Document Type: Article

References (37)

1. Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KM, Thompson TJ. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: A modelling study. Lancet Diabetes Endocrinol 2014;2:867-874.
2. American Diabetes Association. Standards of medical care in diabetesd2014. Diabetes Care 2014;37(Suppl. 1):S14-S80.
3. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013;34:2444-2452.
4. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119:1728-1735.
5. Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes. Diabetes Care 2003;26:3357-3358.
6. O'Donnell MJ, Xavier D, Liu L, et al.; INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010;376:112-123.
7. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332: 73-78.
8. Kalyani RR, Lazo M, Ouyang P, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care 2014;37: 830-838.
9. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: A meta-analysis of prospective studies. Diabetes Care 2000;23:962-968.
10. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901-906.
11. Gorter PM, Visseren FL, Algra A, van der Graaf Y; SMART Study Group. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with type 2 diabetes. The SMART study. Diabet Med 2007; 24:1352-1360.
12. Alberts MJ, Bhatt DL, Mas JL, et al.; REduction of Atherothrombosis for Continued Health Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009;30:2318-2326.
13. Achterberg S, Cramer MJ, Kappelle LJ, et al. Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: The SMART study. Eur J Cardiovasc Prev Rehabil 2010;17:424-430.
14. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second Manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15: 773-781.
15. Hirsch AT, Haskal ZJ, Hertzer NR, et al.; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter- Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by theAmerican Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-1312.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27:1487-1495.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470.
19. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145- 157.
20. Lanzer P, Boehm M, Sorribas V, et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J 2014;35:1515-1525.
21. Lüscher TF. The endothelium and cardiovascular diseaseda complex relation. N Engl J Med 1994;330:1081-1083.
22. Ross R. Atherosclerosisdan inflammatory disease. N Engl J Med 1999;340:115-126.
23. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150-159.
24. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
25. Jensen LO, Maeng M, Thayssen P, et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2012; 109:629-635.
26. Machecourt J, Danchin N, Lablanche JM, et al.; EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimuseluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501-508.
27. Lüscher TF, Steffel J, Eberli FR, et al. Drugeluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058.
28. Silva JA, Ramee SR, White CJ, et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999;138:446- 455.
29. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012;55:2154-2162.
30. Boonman-de Winter LJ, Hoes AW, Cramer MJ, de Jongh G, Janssen RR, Rutten FH. Prognosis of screen-detected heart failure with reduced and preserved ejection fraction in patients with type 2 diabetes. Int J Cardiol 2015;185:162-164.
31. Brophy S, Cooksey R, Gravenor MB, et al. Population based absolute and relative survival to 1 year of peoplewith diabetes following amyocardial infarction: A cohort study using hospital admissions data. BMC Public Health 2010;10:338.
32. Hillegass WB, Patel MR, Klein LW, et al. Long-term outcomes of older diabetic patients after percutaneous coronary stenting in the United States: A report from the National Cardiovascular Data Registry, 2004 to 2008. J Am Coll Cardiol 2012;60:2280-2289.
33. Nakatani D, Sakata Y, Suna S, et al.; Osaka Acute Coronary Insufficiency Study (OACIS) Investigators. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2013;77:439-446.
34. Venketasubramanian N, Röther J, Bhatt DL, et al.; REACH Investigators. Two-year vascular event rates in patients with symptomatic cerebrovascular disease: The REACH registry. Cerebrovasc Dis 2011;32:254-260.
35. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172:95-105.
36. Goessens BM, van der Graaf Y, Olijhoek JK, Visseren FL; SMART Study Group. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 2007;45: 47-54.
37. Sanclemente C, Yeste M, Suarez C, et al.; FRENA investigators. Predictors of outcome in stable outpatients with peripheral artery disease. Intern Emerg Med 2014;9:69-77.